Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study

A. Santoro, H. Bredenfeld, L. Devizzi, H. Tesch, V. Bonfante, S. Viviani, F. Fiedler, H. Soto Parra, C. Benoehr, M. Pacini, G. Bonadonna, V. Diehl

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Purpose: To explore the use of gemcitabine for the treatment of patients with relapsing or refractory Hodgkin's disease. Patients and Methods: Eligible patients had measurable disease and more than one previous chemotherapy regimen. Patients previously treated with high-dose chemotherapy with autologous bone marrow or peripheral stem-cell support were not included. Gemcitabine, 1,250 mg/m2, was administered as a 30-minute intravenous infusion on days 1, 8, and 15 of each 28-day cycle of therapy. The dosing schedule remained fixed, and any dose of gemcitabine that could not be given on time was omitted. Patients who had not experienced any hematalogic or nonhematalogic toxicity after one complete cycle of therapy were permitted to have subsequent doses increased by 20%: that is, from 1,250 mg/m2 to 1,500 mg/m2. Results: Of the 23 enrolled patients, 22 were assessable for response; all 23 patients were included in the efficacy analysis. Disease status for two patients (9%) reached a state of complete remission, and seven patients (30%) achieved a partial response, for an overall response rate of 39% (95% confidence interval, 19.7% to 61.5%). The likelihood of achieving a response was not influenced by a patients' main pretreatment characteristics or by their response to their last prior chemotherapy. The median duration of response was 6.7 months (range, 2 to 33+ months), and the median overall survival time was 10.7 months (range, 4 to 34.7+ months). In general, toxicities were mild; no treatment-related deaths occurred, and only one life-threatening adverse event was reported for this study. Conclusion: Gemcitabine was shown to be active in heavily pretreated patients with Hodgkin's disease, producing a response rate of 39%. Additionally, drug-related toxicities were mild, which thus suggests the possible inclusion of gemcitabine in an earlier phase of treatment. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish
Pages (from-to)2615-2619
Number of pages5
JournalJournal of Clinical Oncology
Volume18
Issue number13
Publication statusPublished - Jul 2000

Fingerprint

gemcitabine
Hodgkin Disease
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gemcitabine in the treatment of refractory Hodgkin's disease : Results of a multicenter phase II study. / Santoro, A.; Bredenfeld, H.; Devizzi, L.; Tesch, H.; Bonfante, V.; Viviani, S.; Fiedler, F.; Soto Parra, H.; Benoehr, C.; Pacini, M.; Bonadonna, G.; Diehl, V.

In: Journal of Clinical Oncology, Vol. 18, No. 13, 07.2000, p. 2615-2619.

Research output: Contribution to journalArticle

Santoro, A, Bredenfeld, H, Devizzi, L, Tesch, H, Bonfante, V, Viviani, S, Fiedler, F, Soto Parra, H, Benoehr, C, Pacini, M, Bonadonna, G & Diehl, V 2000, 'Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study', Journal of Clinical Oncology, vol. 18, no. 13, pp. 2615-2619.
Santoro, A. ; Bredenfeld, H. ; Devizzi, L. ; Tesch, H. ; Bonfante, V. ; Viviani, S. ; Fiedler, F. ; Soto Parra, H. ; Benoehr, C. ; Pacini, M. ; Bonadonna, G. ; Diehl, V. / Gemcitabine in the treatment of refractory Hodgkin's disease : Results of a multicenter phase II study. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 13. pp. 2615-2619.
@article{57748d38faaa48ffb246ba835dd80920,
title = "Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study",
abstract = "Purpose: To explore the use of gemcitabine for the treatment of patients with relapsing or refractory Hodgkin's disease. Patients and Methods: Eligible patients had measurable disease and more than one previous chemotherapy regimen. Patients previously treated with high-dose chemotherapy with autologous bone marrow or peripheral stem-cell support were not included. Gemcitabine, 1,250 mg/m2, was administered as a 30-minute intravenous infusion on days 1, 8, and 15 of each 28-day cycle of therapy. The dosing schedule remained fixed, and any dose of gemcitabine that could not be given on time was omitted. Patients who had not experienced any hematalogic or nonhematalogic toxicity after one complete cycle of therapy were permitted to have subsequent doses increased by 20{\%}: that is, from 1,250 mg/m2 to 1,500 mg/m2. Results: Of the 23 enrolled patients, 22 were assessable for response; all 23 patients were included in the efficacy analysis. Disease status for two patients (9{\%}) reached a state of complete remission, and seven patients (30{\%}) achieved a partial response, for an overall response rate of 39{\%} (95{\%} confidence interval, 19.7{\%} to 61.5{\%}). The likelihood of achieving a response was not influenced by a patients' main pretreatment characteristics or by their response to their last prior chemotherapy. The median duration of response was 6.7 months (range, 2 to 33+ months), and the median overall survival time was 10.7 months (range, 4 to 34.7+ months). In general, toxicities were mild; no treatment-related deaths occurred, and only one life-threatening adverse event was reported for this study. Conclusion: Gemcitabine was shown to be active in heavily pretreated patients with Hodgkin's disease, producing a response rate of 39{\%}. Additionally, drug-related toxicities were mild, which thus suggests the possible inclusion of gemcitabine in an earlier phase of treatment. (C) 2000 by American Society of Clinical Oncology.",
author = "A. Santoro and H. Bredenfeld and L. Devizzi and H. Tesch and V. Bonfante and S. Viviani and F. Fiedler and {Soto Parra}, H. and C. Benoehr and M. Pacini and G. Bonadonna and V. Diehl",
year = "2000",
month = "7",
language = "English",
volume = "18",
pages = "2615--2619",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - Gemcitabine in the treatment of refractory Hodgkin's disease

T2 - Results of a multicenter phase II study

AU - Santoro, A.

AU - Bredenfeld, H.

AU - Devizzi, L.

AU - Tesch, H.

AU - Bonfante, V.

AU - Viviani, S.

AU - Fiedler, F.

AU - Soto Parra, H.

AU - Benoehr, C.

AU - Pacini, M.

AU - Bonadonna, G.

AU - Diehl, V.

PY - 2000/7

Y1 - 2000/7

N2 - Purpose: To explore the use of gemcitabine for the treatment of patients with relapsing or refractory Hodgkin's disease. Patients and Methods: Eligible patients had measurable disease and more than one previous chemotherapy regimen. Patients previously treated with high-dose chemotherapy with autologous bone marrow or peripheral stem-cell support were not included. Gemcitabine, 1,250 mg/m2, was administered as a 30-minute intravenous infusion on days 1, 8, and 15 of each 28-day cycle of therapy. The dosing schedule remained fixed, and any dose of gemcitabine that could not be given on time was omitted. Patients who had not experienced any hematalogic or nonhematalogic toxicity after one complete cycle of therapy were permitted to have subsequent doses increased by 20%: that is, from 1,250 mg/m2 to 1,500 mg/m2. Results: Of the 23 enrolled patients, 22 were assessable for response; all 23 patients were included in the efficacy analysis. Disease status for two patients (9%) reached a state of complete remission, and seven patients (30%) achieved a partial response, for an overall response rate of 39% (95% confidence interval, 19.7% to 61.5%). The likelihood of achieving a response was not influenced by a patients' main pretreatment characteristics or by their response to their last prior chemotherapy. The median duration of response was 6.7 months (range, 2 to 33+ months), and the median overall survival time was 10.7 months (range, 4 to 34.7+ months). In general, toxicities were mild; no treatment-related deaths occurred, and only one life-threatening adverse event was reported for this study. Conclusion: Gemcitabine was shown to be active in heavily pretreated patients with Hodgkin's disease, producing a response rate of 39%. Additionally, drug-related toxicities were mild, which thus suggests the possible inclusion of gemcitabine in an earlier phase of treatment. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: To explore the use of gemcitabine for the treatment of patients with relapsing or refractory Hodgkin's disease. Patients and Methods: Eligible patients had measurable disease and more than one previous chemotherapy regimen. Patients previously treated with high-dose chemotherapy with autologous bone marrow or peripheral stem-cell support were not included. Gemcitabine, 1,250 mg/m2, was administered as a 30-minute intravenous infusion on days 1, 8, and 15 of each 28-day cycle of therapy. The dosing schedule remained fixed, and any dose of gemcitabine that could not be given on time was omitted. Patients who had not experienced any hematalogic or nonhematalogic toxicity after one complete cycle of therapy were permitted to have subsequent doses increased by 20%: that is, from 1,250 mg/m2 to 1,500 mg/m2. Results: Of the 23 enrolled patients, 22 were assessable for response; all 23 patients were included in the efficacy analysis. Disease status for two patients (9%) reached a state of complete remission, and seven patients (30%) achieved a partial response, for an overall response rate of 39% (95% confidence interval, 19.7% to 61.5%). The likelihood of achieving a response was not influenced by a patients' main pretreatment characteristics or by their response to their last prior chemotherapy. The median duration of response was 6.7 months (range, 2 to 33+ months), and the median overall survival time was 10.7 months (range, 4 to 34.7+ months). In general, toxicities were mild; no treatment-related deaths occurred, and only one life-threatening adverse event was reported for this study. Conclusion: Gemcitabine was shown to be active in heavily pretreated patients with Hodgkin's disease, producing a response rate of 39%. Additionally, drug-related toxicities were mild, which thus suggests the possible inclusion of gemcitabine in an earlier phase of treatment. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0033932803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033932803&partnerID=8YFLogxK

M3 - Article

C2 - 10893294

AN - SCOPUS:0033932803

VL - 18

SP - 2615

EP - 2619

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -